Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Court dismissed lawsuit due to lack of FDA approval for LPCN-1021 and not on merits of case
Clarus will be allowed to refile its lawsuit, if necessary
NORTHBROOK, Ill., Oct. 13, 2016 -- Clarus Therapeutics, Inc. (“Clarus” or the “Company”) today reported that its patent infringement lawsuit against Lipocine, Inc. (NASDAQ:LPCN) that had been filed in U.S. District Court in Delaware has been dismissed. The court found that there was not an immediate reason to hear the case given Lipocine’s failure to receive FDA market approval for LPCN-1021. Importantly, the decision was made without ruling on the validity of Clarus’s U.S. Patent 8,828,428 and other merits of the case. While Clarus disagrees with the court’s ruling, no further action will be taken unless LPCN-1021 is approved by the FDA, at which time Clarus will have the option to refile its patent infringement lawsuit.
Dr. Robert Dudley, President and CEO of Clarus and co-inventor of the patent in question, stated, “We remain strong in our belief that LPCN-1021 infringes Clarus’s ‘428 patent and it is particularly noteworthy that the court did not rule on this central fact. If LPCN-1021 were to be approved by the FDA, our plan would be to vigorously pursue all avenues to keep Lipocine’s LPCN-1021 from entering the market and protect the intellectual property, accompanying financial investment and years of work we have invested in JATENZO® – our oral TRT product. We continue to advance the development of JATENZO® which is being evaluated in a new Phase 3 study that is near completion.”
About Clarus Therapeutics
Clarus is an emerging men’s specialty pharmaceutical company developing and preparing for the commercial launch of JATENZO, an oral testosterone replacement therapy. JATENZO is a T prodrug that, if approved by the FDA, will be used to treat men diagnosed with testosterone deficiency together with an associated medical condition, also known as hypogonadism. Clarus owns the worldwide, royalty-free commercialization rights for JATENZO. For more information, please visit: www.clarustherapeutics.com.
Investor Contact: The Ruth Group David Burke Tel: 646-536-7009 [email protected]
